Enlivex Therapeutics Cash Flow Statement Analysis

Operating, investing, and financing activities in millions USD

Scroll to see more
Cash flow statement showing operating, investing, and financing activities for Enlivex Therapeutics Ltd. (ENLV) - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Operating Activities
Net Income-15.01-29.07-31.06-14.47-11.82
Depreciation & Amortization0.550.840.780.550.29
Stock Based Compensation0.001.952.712.910.67
Change in Working Capital-1.22-1.820.80-1.36-0.31
Change in Accounts Receivable0.430.000.000.000.00
Change in Accounts Payable-0.02-1.121.170.440.04
Change in Other Working Capital-1.64-0.700.83-1.80-0.34
Other Operating Activities2.680.700.830.410.17
Net Cash from Operating Activities-13.01-23.52-23.95-17.54-11.01
Investing Activities
Capital Expenditures-0.10-0.24-8.12-1.63-1.02
Purchases of Investments-32.37-25.87-1.91-36.78-19.96
Sales/Maturities of Investments39.240.3072.5567.630.00
Other Investing Activities2.290.000.000.000.00
Net Cash from Investing Activities9.06-25.9762.52-38.41-20.98
Financing Activities
Common Stock Issued6.450.510.1565.4435.58
Other Financing Activities0.00-0.150.00-4.46-2.50
Net Cash from Financing Activities6.450.360.1560.9833.08
Summary
Effect of Forex Changes on Cash0.000.000.00-0.410.00
Net Change in Cash2.51-49.1338.724.621.49
Cash at Beginning of Period1.2350.3611.647.010.00
Cash at End of Period3.731.2350.3611.640.00
Free Cash Flow-13.11-23.76-32.08-19.17-12.03